alexr.bsky.social
personalized cancer immunotherapy = genomics + immunology + machine learning + oncology
(pirl.unc.edu)
1,016 posts
5,532 followers
948 following
Regular Contributor
Active Commenter
comment in response to
post
OpenAI (and Future House Falcon, which seems comparable)
comment in response to
post
Just added it!
Link if anyone else wants it:
bsky.app/profile/did:...
comment in response to
post
Deep Research has significantly accelerated the research aims of my lab. There are half baked ideas that I never had time to sufficiently scope out that are turning into concrete and ambitious experiments because I have a skilled literature search assistant on my phone
comment in response to
post
23andme identified several Chronic Poster risk loci
comment in response to
post
Sometimes! I’m not as committed but definitely want this side to win (ie 75%+ of high quality X content moves here, the really ugly stuff stays there)
comment in response to
post
@sergeyf.bsky.social did you make Paper Finder?
comment in response to
post
Mostly o3 + Deep Research, a little bit Future House Falcon
comment in response to
post
You’re one of <10 posters that keep me on here
comment in response to
post
It’s my professional research field for the past ten years, Ben and I run the Personalized Immunotherapy Research Lab at UNC (PIRL.UNC.edu) — he’s also a hematologist, I’m just a computational researcher
comment in response to
post
o3 + Deep Research has accelerated some big pivots and new directions our lab has taken the past few months
Other LLM models and use cases feel neat but low impact by comparison
comment in response to
post
Same experience with TCR patents
comment in response to
post
Yeah, hard to distinguish the two!
Symptoms started a few months after trial (early 2021), got Covid about six months later and I think it was more noticeable after
comment in response to
post
Didn’t see that! I also wonder how sensitive monitoring is to chronic but not very serious symptoms like the ones I had
comment in response to
post
I’m very curious about the pericarditis study, I was in the original trial and definitely felt some mysterious chest pains in the 2ish years after that are hard to attribute to anything confidently but made me wonder
comment in response to
post
I think that is largely what happens now but in my experience the translational step is still glacial and uncertain
comment in response to
post
How do you do that on a very casual amount of effort?
comment in response to
post
But in Western liberal circles I think Hebrew has quickly risen to the top
comment in response to
post
Depending on the social context I think Russian, Hebrew, and Arabic can all cause some problems— I think past that you get into more local / less globally covered conflicts where being a foreigner learning the language might just be confusing
comment in response to
post
I kinda like the approach to economics which is just maybe if you're just mad online hard enough about scarcity you won't have to deal with its consequences. Very postmodern, appropriate to our era.
comment in response to
post
There’s a market but ecosystem to actually deliver on the therapy is very early, lots of friction with eg CDMOs tooled for scale even if you can open an IND
comment in response to
post
Realizing in this convo I’m extremely empirical— I just want to hill climb up to max CD8+ response and am mostly indifferent to the mechanism!
LNP encapsulation of peptides with different adjuvant would be interesting for isolation of role of mRNA (though not sure if LNPs will form with eg CpG)
comment in response to
post
Haha, this paper is really Immunology (tm)
How do you think this connects to the polyIC story though?
comment in response to
post
I think it’s all about cross presentation with long peptides
comment in response to
post
(I prefer the future with robust public institutions but that one feels less likely)
comment in response to
post
I’m not! Matches the lack of ex vivo CD8+ responses in all of the neoAg vaccine trials
comment in response to
post
Just the antigen -- don't think the M57 17mer has any independent immune effect
comment in response to
post
m1Ψ
comment in response to
post
After next round of the bake-off, going to pivot to tumor antigens (once we get some mass spec validation of which ones are real).
For now, read the blog post by @benjamingvincent.bsky.social: pirlblog.substack.com/p/an-experim...
comment in response to
post
We've previously done some calibration on 3 antigens to show that splenocyte IFNg ELISpot correlates well with tetramer staining and circulating T-cell responses, have since been focusing deep dives on single murine CMV 17mer peptide (with MHC-I binding minimal epitope)
comment in response to
post
There is also dollar vans in NYC & Via (startup 15ish years ago).
comment in response to
post
Really remarkable how few papers there are on this style of therapy, trying to use it as a component for something more complex but the space of results is pretty sparse